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Abstract
Background: Guanylyl cyclase-B (GC-B; NPR-B), the receptor for C-type natriuretic peptide
(CNP) is rapidly and effectively desensitized by a factor(s) in serum. Given the potential importance
of this receptor in remodeling after tissue injury, identification of the serum factor(s) is of significant
medical importance.
Results: Partial purification of desensitization activity in serum by DEAE-Sepharose and reverse
phase C18 chromatography, followed by mass spectroscopy, identified peptide sequences identical
to those of apolipoprotein A2 (Apo A2), a known component of high density lipoprotein (HDL).
Apo A2, however, could be eliminated as the active desensitization factor. Never the less,
substantial desensitization activity was associated with purified preparations of bovine or human
HDL. Since HDL is a well-known transporter of various lipids and phospholipids, we extracted
either HDL or partially purified serum preparations with butanol and all activity extracted into the
solvent. Of various lipophilic signaling molecules known to be associated with HDL, a prominent
component is sphingosine-1-phosphate (S1P). We therefore tested authentic S1P as well as other
known components of HDL (sphingosylphosphorylcholine; platelet activating factor) for activity;
only S1P caused desensitization of GC-B. S1P was relatively potent, causing one-half maximal
desensitization of GC-B at concentrations of 5–10 nM. These effects were seen within a few
minutes after addition. Lysophosphatidic acid, another component of serum capable of
desensitizing GC-B, was only effective at Micromolar concentrations. The pathway by which serum
or S1P desensitizes GC-B seems unique in that pertussis toxin failed to inhibit GC-B
desensitization, and yet blocked serum or S1P activation of extracellular signal-regulated kinase
(ERK) or Akt/protein kinase B (Akt/PKB).
Conclusion:  Since the concentrations of S1P that desensitize GC-B are well within serum
physiological ranges, this mitogenic signaling molecule likely functions as a strong adversary of the
CNP/GC-B signaling pathway in the regulation of cell proliferation and other growth factor-induced
phenotypes. The mechanism by which S1P desensitizes GC-B appears different than the known S1P
signaling pathways.
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Background
Atrial natriuretic peptide (ANP1), C-type natriuretic pep-
tide (CNP), and cell-permeant guanosine-3',5'-mono-
phosphate (cGMP) analogs antagonize growth factor-
stimulated proliferation and chemotaxis in cultured
fibroblasts and vascular smooth muscle cells, and CNP
also slows coronary artery restenosis in vivo [1-3]. Con-
versely, serum and certain peptide and phospholipid
growth factors suppress CNP-elevations of cGMP in pri-
mary dermal fibroblasts, BALB-c/3T3 fibroblasts, or NIH/
3T3 fibroblasts that over-express the receptor for CNP,
guanylyl cyclase B (GC-B) [1,4]. Therefore, it has been
suggested that CNP/GC-B and various mitogens oppose
each other in the regulation of tissue remodeling after
injury [1,3,4]. Adult cardiac fibroblasts, for example, syn-
thesize CNP and express GC-B and CNP or cell permeant
analogs of cGMP antagonize increases in DNA and colla-
gen synthesis promoted by serum [5,6]. In previous stud-
ies, a number of growth factors and other agents have
been shown to cause desensitization of guanylyl cyclase A
(GC-A) or GC-B, possibly through the induction of recep-
tor dephosphorylation [1,7,8]. As we compared the
relative potencies of various serum growth factors (plate-
let-derived growth factor, PDGF; lysophosphatidic acid,
LPA; basic fibroblast growth factor, bFGF) to desensitize
GC-B, we realized that serum acted at dilutions where the
above factors could not represent the most active desensi-
tization factor. We then identified a serum factor (sphin-
gosine-1-phosphate; S1P) that causes desensitization of
GC-B at concentrations well within the range of those
found in serum.
Results
Identification of a Protein Component in Purified 
Inhibitory Fractions
Mass spectroscopy identified a tryptic fragment (KAGT-
DLLNFLSSFIDPK) in the purified fractions from the final
HPLC column (Fig 1, fraction 17.5 min) as identical to
bovine ApoA2 [9]. Apolipoprotein A2 (ApoA2), a peptide
Isolation of desensitization activity by reverse-phase  chromatography Figure 1
Isolation of desensitization activity by reverse-phase 
chromatography. Inhibition of CNP-induced elevations of 
cGMP levels in GC-B/3T3 cells by fractions from the second 
analytic C18 column. Fifty-µl aliquots of the 0.5 ml fractions 
were dried and dissolved in 50 µl PBS and 5 µl added to the 
cells in a final volume of 0.5 ml. IBMX (0.25 mM) and CNP 
(20 nM) were added and cGMP levels were determined after 
5 min incubation with CNP as described under Methods. 
Error bars indicate the range of duplicate determinations.
Low serum from a variety of species desensitizes GC-B to  CNP Figure 2
Low serum from a variety of species desensitizes GC-
B to CNP. GCB/3T3 cells were incubated with heat-inacti-
vated serum from the indicated species for 30 min prior to 
adding 0.25 mM IBMX and 20 nM CNP and cGMP contents 
were determined after 5 min of incubation with CNP as 
described under Methods. Error bars indicated the range of 
duplicate determinations.Cell Communication and Signaling 2003, 1 http://www.biosignaling.com/content/1/1/4
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of 76 amino acids, constitutes about 20% of the lipopro-
tein in HDL and functions primarily to modulate lipid
binding of HDL [10]. ApoA2 is also found in bovine
serum free of association with HDL [9]. However, that it
represented a desensitization factor seemed unlikely after
we compared the activity of serum from many different
species (Fig 2). The serum of all species tested caused
desensitization of GC-B at about the same relative serum
concentration, and yet chicken serum has been reported
to express only barely detectable levels of ApoA2 [11].
Thus, Apo A2 was not the active factor.
Desensitization of GC-B by HDL
Given that ApoA2 is a constituent of HDL, we compared
purified preparations of human and bovine HDL for
desensitization activity and both displayed similarly high
activities based on protein content (Fig 3). The results also
established that serum desensitization activity is directly
associated with HDL from both human plasma and
bovine serum, and is not an artifact of the purification
procedure.
Extraction of lipid components into Butanol
HDL transports various phospholipids and sphingolipids
[12,13], and so we asked whether the active component
was lipophilic. HDL preparations were subjected to buta-
nol extraction and essentially all activity was extracted
into the organic solvent phase (Fig 4A). In a separate series
of experiments on the partially purified factor prepara-
tions from bovine serum (first C18 column), butanol also
extracted the desensitization activity (Fig 4B).
Human and bovine HDL desensitize GC-B in GCB/3T3 cells Figure 3
Human and bovine HDL desensitize GC-B in GCB/
3T3 cells. Human and bovine HDL preparations were 
added to GC-B/3T3 cells for 30 min and desensitization of 
GC-B was then determined as described under Methods. 
Fetal bovine serum (FBS) was diluted in PBS and cells treated 
as described for the HDL preparations. Results are the mean 
-/+ S.D. (n = 4).
Desensitization activity is extracted by butanol Figure 4
Desensitization activity is extracted by butanol. A. 
Butanol extraction of human HDL. One mg human HDL pro-
tein was extracted with 33% n-butanol/20 mM acetic acid as 
described under Methods and desensitization activity in the 
upper ("B") and lower ("W") phases determined. HDL repre-
sents the starting material for the butanol extraction and was 
included with cells at 10 µg/ml. B. Butanol extraction of a 
partially purified serum preparation. Active fractions (about 4 
ml) from the initial C18 column were dried and extracted 
with 33% n-butanol/20 mM acetic acid as described under 
Methods and diluted 1000-fold into the cell incubation for 
measurement of desensitization activity in the upper ("B") 
and lower ("W") phases. SM represents the pooled active 
C18 column fractions prior to butanol extraction diluted 
1000-fold into the cell incubation.Cell Communication and Signaling 2003, 1 http://www.biosignaling.com/content/1/1/4
Page 4 of 9
(page number not for citation purposes)
Identification of Serum Factor
Lysophosphatidic acid (LPA), is also present in serum at
concentrations of 2–10 µM [14], but was not found as a
component of the HDL butanol extract (not shown). Both
S1P and LPA are released into serum by activated platelets
[15,14] and therefore represent potential regulators of tis-
sue remodeling at sites of injury. S1P has been suggested
to bind to G-protein coupled cell surface receptors
(S1PR1–5) homologous to LPA receptors (LPAR1–3); it is
mitogenic when added to fibroblasts and smooth muscle
cells in culture [16]. S1P also has been suggested to serve
as an intracellular second messenger for the mitogenic
actions of serum or PDGF in fibroblasts or smooth muscle
cells [17]. S1P therefore became a primary candidate as
the serum and HDL desensitization factor. Sphingosine-1-
phosphate rapidly desensitized GC-B (Fig 5) and at the
same time induced rapid increases of pERK and pAkt in
the GCB/3T3 cell line (Fig 5, inset). The S1P concentration
used (100 nM) desensitized with a half-time of about 5–
10 min and was maximal by 20 min prior to CNP addi-
tion. S1P was also very potent, being effective at low nM
concentrations, and was much more potent than LPA (Fig
6A). The approximate 100-fold shift in the CNP concen-
tration-response curve (Fig 6B) would effectively desensi-
tize GC-B over the physiological concentration range for
CNP (Fig 6B). In addition to S1P, we also tested two other
known components of HDL, sphingosylphosphorylcho-
line and platelet activating factor, and neither demonstra-
bly desensitized GC-B (Fig 7). The IC50 of 5–10 nM for
S1P, similar to the nM Kd's reported for all of the S1P
receptors, including Gi-promoted inhibition of adenylate
cyclase [17], together with the rapid increases in pERK and
pAkt (Fig 5, inset) initially suggested it acted through cell
surface receptors to desensitize GC-B. The proposed
intracellular pathway for S1P seems to require µM
amounts for detectable responses [17,18].
Desensitization in other Cells
The potent effects of S1P on GC-B signaling are not con-
fined to the immortalized murine fibroblasts over-
expressing GC-B in the above studies. S1P significantly
suppressed CNP/GCB signaling in a human aortic smooth
muscle primary cell line with an IC50 of 5–10 nM (Fig 8A)
and shifted the dose response curve for CNP about 100-
fold higher (Fig 8B) responses similar to those of the
GCB/3T3 cell line (Fig 6). LPA also suppressed cGMP ele-
vations in this cell line but was far less effective than S1P.
The suppression of cGMP levels in these cells by the
mitogens, S1P or LPA, is consistent with our earlier obser-
vations that the antimitogenic effects of cGMP can be
antagonized by mitogen-mediated inhibition of cell sur-
face guanylyl cyclase signaling [1]. In fact, it has been pos-
tulated that S1P contributes to restenosis following
coronary artery angioplasty through the promotion of vas-
cular smooth muscle proliferation [19]. CNP, in contrast,
inhibits restenosis [2]. Thus an adversarial relationship
between CNP and S1P signaling pathways may be opera-
tive in event such as vascular smooth muscle remodeling.
Uniqueness of the Desensitization Pathway
Dependent on the specific receptors expressed, S1P stim-
ulates diverse cell functions such as proliferation, differen-
tiation, and motility. The most widely distributed
receptors, S1PR1–3, are coupled to pertussis toxin-sensitive
Gi/0 [17]. However, pertussis toxin was completely ineffec-
tive in blocking desensitization of GC-B by S1P, while it
completely prevented increases in pERK and pAkt (Fig 9).
Thus, the pathway of S1P desensitization of GC-B is
Sphingosine-1-phosphate rapidly desensitizes GC-B Figure 5
Sphingosine-1-phosphate rapidly desensitizes GC-B. 
S1P (100 nM) was added to GCB/3T3 cells at the indicated 
times before addition of 20 nM CNP and 5 min later the 
reaction was terminated with 0.5 N perchloric acid and 
cGMP accumulation determined as in Methods. Inset; S1P 
(100 nM) was added to cells for the indicated times and the 
levels of pERK and pAkt determined by Western blot as 
described in Methods.Cell Communication and Signaling 2003, 1 http://www.biosignaling.com/content/1/1/4
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apparently not coupled to Gi/0. Likewise, serum-desensiti-
zation of GC-B was unaltered by pertussis toxin, even
though pAkt activation was completely blocked; likewise,
pERK activation was substantially reduced under the same
conditions. Partial inhibition of serum-elevated pERK by
pertussis toxin is consistent with the presence of both pep-
tide growth factors (e.g.; bFGF and PDGF) that do not sig-
nal through G-protein coupled receptors, and
phospholipid mitogen-activated G-protein coupled recep-
tors. The complete inhibition of serum-induced pAkt acti-
vation by pertussis toxin suggests that pAkt regulation is
tied exclusively to G-protein coupled receptors (GPCRs)
in the fibroblast 3T3 cell line. However, pertussis toxin,
Wortmannin, and C3-exotoxin, agents that block G-pro-
tein coupled receptors, PI3-kinase, and Rho kinase,
respectively, failed to inhibit the desensitization of GC-B
induced by serum in primary human dermal fibroblasts
(not shown). Furthermore, ATP and ATPγS, G-protein
coupled P2 receptor agonists [20], activated the MAP
kinase pathway without altering GC-B signaling (not
shown). These results clearly dissociate many of the
known mitogen-activated pathways from the pathway of
GC-B desensitization, and therefore seem to also elimi-
nate a number of the known receptors from consideration
as mediators of the desensitization.
Conclusions
A unifying model for the actions of various mitogens and
S1P to desensitize GC-B appears to require the existence of
receptors that are not coupled to Gi. These could be cell
surface or intracellular receptors. In the model of Spiegel
and colleagues [17,21] PDGF or serum activate sphingo-
sine kinase, which then catalyzes increased formation of
S1P. S1P may then act on intracellular receptors and
bypass the G-coupled receptors on the plasma membrane.
Such a pathway would provide a unifying model to
explain the common action of various mitogens to desen-
sitize the CNP receptor independent of ERK or Akt activa-
S1P is a potent desensitization agent Figure 6
S1P is a potent desensitization agent. A, GC-B/3T3 cells were incubated with the indicated concentrations of S1P or LPA 
for 30 min and the responses to 20 nM CNP determined as described under Methods. B, GC-B/3T3 cells were incubated with 
100 nM S1P 30 min and responses to the indicated amounts of CNP determined as described under Methods. Results are 
given as the mean of duplicate wells -/+ the range of duplicates, error bars.Cell Communication and Signaling 2003, 1 http://www.biosignaling.com/content/1/1/4
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tion. On the other hand, possibly the various mitogens,
including S1P, act through a unique pathway not involv-
ing Gi or the activation of pathways such as those of ERK
or Akt.
Methods
Reagents
The contents of cGMP in cultured cell lines were deter-
mined as previously described. Human aortic smooth
muscle cells were from Clonetics and cultured as
instructed by the supplier. NIH/3T3 cells over-expressing
rat GC-B (GCB/3T3) were as previously described [22];
continuous passaging of this cell line can result in
decreased expression of GCB (Fig. 1vs Fig 7). Human HDL
was from Biotechnology Industries and was diluted in
phosphate-buffered saline (PBS) just prior to
experimentation. Peptide sequencing was by the Mass
Spectroscopy Facility at UT Southwestern Medical Center
in Dallas. Pertussus toxin was from List Biochemicals and
fetal bovine serum (FBS) was from Atlanta Biologicals.
Desensitization Assay
Desensitization of GC-B to the ligand CNP was deter-
mined in duplicate or quadruplicate as described previ-
ously [1]. Confluent cells in 24-well tissue culture plates
were placed in serum-deficient DMEM for 24 to -48 h and
were then transferred to fresh serum-deficient medium 2
h prior to experimental treatments. Stock solutions of
CNP (Peninsula Biochemicals), LPA and S1P (Sigma
Aldrich) were diluted in fatty acid-free bovine serum albu-
min (Sigma Aldrich) at 100-times the concentration in the
cell reactions. Samples were added to the cells for 30 min
prior to the addition of 0.25 mM 3-isobutyl-1-methylxan-
thine for 10 min; this was followed by the addition of
CNP to a 20 nM final concentration for 5 min. Addition
of perchloric acid to a final concentration of 0.5 N termi-
nated the cell reactions. cGMP content of each well was
determined in duplicate by radioimmunoassay as
described [1]. Bovine HDL (d = 1.063–1.21) was isolated
from heat-inactivated fetal bovine serum (FBS) by
centrifugation into KBr as described for isolation of
human plasma HDL [23]. The resulting preparations were
at least 90% pure as judged by protein staining (GelCode
Blue Stain Reagent (Pierce)) following sodium dodecyl-
sulfate(SDS)-polyacrylamide gel electrophoresis.
Butanol extraction of HDL or partially purified serum factor
One mg human HDL in 0.8 ml PBS/20 mM acetic acid
was mixed with 0.4 ml n-butanol/20 mM acetic acid and
the phases separated by centrifugation as described by
English et al. [15]. Twenty-µl aliquots of the upper
("butanol') and lower ("water") phases were dried and
dissolved in 50 µl PBS and 5 µl used for cell incubation.
For the partially purified serum factor preparation, active
fractions from the initial C18 column were dried and the
residue dissolved in 4 ml PBS/20 mM acetic acid and 2 ml
n-butanol/20 mM acetic acid added. Further processing
was as described above except that the 50-µl aliquots were
dried and dissolved in 500 µl PBS.
Western Blots
The phosphorylated forms of extracellular signal-regu-
lated kinases 1 and 2 (pERK1/2) were determined by
Western blot using rabbit antisera to pERKs (Promega)
diluted 1:20,000 as previously described [1] with the
modification that the horseradish peroxidase-linked
secondary antibody (goat anti-rabbit IGG) was diluted
1:500,000 and chemiluminescence detected by Pierce
SuperSignal West Femto reagent. Phosphorylated Akt/
PKB (pAkt) was detected using rabbit antisera to phos-
phoserine 473 (Cell Signaling Technology) diluted
1:1000 and the secondary antibody diluted 1:250,000
and detected as above.
Purification of Desensitization Activity
Isolation of a desensitization component of heat-inacti-
vated FBS was accomplished using a combination of
anion exchange chromatography (DEAE) and C18-reverse-
phase chromatography. Generally, three hundred ml
serum was diluted with 4 volumes 25 mM Tris, pH 7.8–50
mM NaCl and mixed with 200 ml DEAE-Sepharose, equil-
ibrated in the same buffer overnight at 8°C. The mixture
was filtered, washed with 1000 ml 25 mM Tris, pH 7.8–
Sphingosylphosphorylcholine and platelet activating factor fail  to desensitize GC-B Figure 7
Sphingosylphosphorylcholine and platelet activating 
factor fail to desensitize GC-B. S1P, sphingosylphospho-
rylcholine (SPC) or platelet activating factor (PAF) were 
added to the final concentrations indicated. The assays for 
GC-B desensitisation were as described in Methods.Cell Communication and Signaling 2003, 1 http://www.biosignaling.com/content/1/1/4
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100 mM NaCl and the washed DEAE Sepharose placed in
a 5 cm diameter column. Protein was eluted from the
DEAE-Sepharose with 500 ml 25 mM Tris, pH 7.8–200
mM NaCl and 10-ml fractions were collected. Fractions
with an A280 greater than 1.0 were pooled (about 100 ml)
and acetic acid and triflouroacetic acid (TFA) were added
to final concentrations of 10% and 0.1%, respectively. The
acidified fractions were applied to 3 C18 cartridges (Sep-
Pak Plus C18, Waters) equilibrated in 0.1% TFA and each
washed with 20 ml 40% acetonitrile-0.1% TFA prior to
elution of retained material with 10-ml 60% acetonitrile-
0.1% TFA per cartridge. The pooled eluates were diluted
approximately 3-fold with 0.1% TFA and applied to a C18
column (Vydac 218TP510) equilibrated in 35% ace-
tonitrile-0.1% TFA at a flow rate of 2-ml/min. The column
was washed for 10 min with 35%acetonitrile-0.1% fol-
lowed by 49% acetonitrile-0.1% TFA for 10 min and then
a linear 49%–53% acetonitrile gradient over 40 min.
Inhibitory activity in the 2-ml fractions was monitored
using inhibition of CNP-elevated cGMP in the GC-B/3T3
cell line. The fractions eluting at approximately 51% ace-
tonitrile contained significant desensitization activity. The
active fractions were pooled, diluted 3-fold in 0.1% TFA
and applied to an analytic C18 column (Vydac 218TP54)
equilibrated in 5% acetonitrile-0.1% TFA followed with
48.8% % acetonitrile-0.1% TFA for 10 min and then with
a linear 48.8%–50.3% acetonitrile-0.1% TFA gradient for
65 min. Active fractions eluting at approximately 50 %
acetonitrile were diluted with 2 volumes 0.1% TFA and
reapplied to the analytic C18 column equilibrated in 5%
acetonitrile-0.1% TFA, washed for 5 min with 5% ace-
tonitrile-0.1% TFA and then for 5 min with 48% ace-
tonitrile-0.1% TFA. Desensitization activity was eluted
with a linear 48–49% acetonitrile-0.1% TFA gradient
obtained over 60 min at 1 ml/min. Active fractions con-
tained a single symmetrical peak of absorbance at 280 nm
that co-eluted with inhibitory activity (Fig 1).
S1P potently desensitizes GC-B in human aortic smooth muscle cells Figure 8
S1P potently desensitizes GC-B in human aortic smooth muscle cells. A, cells were incubated with 100 nM S1P for 
30 min and the responses to the indicated concentrations of CNP determined as described under Methods. B, cells were incu-
bated for 30 min with the indicated concentrations of S1P or LPA as indicated and the responses to 20 nM CNP determined as 
described under Methods. Results are expressed as the mean of duplicate observations -/+ the range of duplicates.Cell Communication and Signaling 2003, 1 http://www.biosignaling.com/content/1/1/4
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Pertussis toxin does not block GC-B desensitization by 100  nM S1P or by 1% fetal bovine serum Figure 9
Pertussis toxin does not block GC-B desensitization 
by 100 nM S1P or by 1% fetal bovine serum. GC-B/3T3 
cells were incubated where indicated with 100 ng/ml pertus-
sis toxin for 24 h prior to a 30 min incubation with 100 nM 
S1P or 1% fetal bovine serum as indicated. CNP responses 
following these treatments were determined as described 
under Methods. Results are the mean of duplicate observa-
tions -/+ the range of duplicates. Inset, cells were incubated 
for 10 min following pertussis treatment as described above 
and the levels of pERK and pAkt were determined as 
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